Market close: NZ stocks buckle, sink to lowest point for 2023
Comments from the US Fed did little to alleviate fears.
AdvertisementAdvertise with NZME.
Latest fromMarkets
Market close: Geopolitics, high yields drive NZ stocks lower
The S&P/NZX50 index was at 11,135.58, down 85.90 points or 0.77 per cent.
Market close: NZ market flattens as investors mull over data
The S&P/NZX 50 Index edged up 0.06 per cent.
Market close: Stocks lifts after surprise inflation data
The S&P/NZX 50 Index edged up 0.26 per cent.
NZ dollar firms v Aussie after election, Fletcher Building tanks
Fletcher Building resumed trading today after being in a halt since Wednesday.
Mark Lister: What might the conflict in Israel mean for markets?
OPINION: Investors should take a safety-first approach and avoid making rash decisions.
Market close: Stocks slip as mystery buyer sizes up Sky TV
New Zealand's sharemarket ended weaker despite a rally in Sky TV.
Market close: NZ market edges up while Fletcher Building goes into trading halt
The S&P/NZX 50 Index rose 13.1 points, or 0.12 per cent.
Market close: NZ market enjoys positive bounce
International funds coming in helped propel the local market.
Will the NZ sharemarket do better under a new Government?
How the NZ sharemarket has performed previously when the Government has changed.
Market close: NZ market flat as RBNZ keeps OCR on hold
It’s not just pre-election jitters that are bleeding into the quiet market.
Market close: NZ market flat as RBA pulls the handbrake
Will the Reserve Bank of New Zealand follow the RBA's line of thinking – or go rogue?
Cannasouth needs to raise capital, job losses coming
The company is waiting for its medicinal cannabis products to be verified.
Market close: Pacific Edge falls as NZ market sinks into the red
No reason for optimism as we enter 'bear killer' month.
Futures points to another big gain in dairy prices
Some dairy gains expected - but is the futures market pricing overcooked?
Market close: The Warehouse, bond yields drive sharemarket down
The S&P/NZX50 Index fell by more than 1 per cent.
Fonterra shareholder farm numbers tumble, but milk market share is king
Watchdog says it's more important that Fonterra is the processor of choice.
Market close: Eroad’s discounted capital raise met with weak take-up
The NZ sharemarket was down as investors press pause.
Market close: AustralianSuper ups its stake in SkyCity
New Zealand’s benchmark share index edged slightly higher.
Market close: Fonterra rebound enlivens flat trading on NZX
Units in Fonterra rallied sharply after a better-than-expected result.
Market close: NZ market flattens out as KMD Brands falls almost 5pc
The S&P/NZX 50 Index fell 0.2 per cent.
Billion-dollar baby: KMD Brands reports more than $1b in full-year group sales
The retailer had its first year of “uninterrupted trade” post-pandemic.
Dairy prices up at GDT auction this morning
Prices for several crucial exports up again at latest auction.
Market close: NZ market follows the US as investors wait for Fed’s decision
Elsewhere in the markets, Synlait bounced back after a big fall yesterday.
NZ market edges up while Synlait Milk shares drop 10 per cent
A2 Milk wants to cancel Synlait’s exclusive milk formula production and supply deal.
Sealord says new deal will make it biggest seafood company
Fish n' chip shop became a major company. Now Sealord wants it.
Market close: Short-lived joy on markets
Yesterday's half a per cent gain is all but forgotten.
Market close: Briscoe Group helps lift sharemarket after rough trot
The New Zealand sharemarket broke a sequence of down days.
Market close: NZ stocks slip further on the back of under-pressure Ebos
The index has fallen in eight of the last nine trading days.
Market close: How a weight loss drug is causing trouble for F&P Healthcare
GLP-1 has been wreaking havoc on healthcare stocks around the world.
Catalytic converter theft sparked huge car business fire
An investigation has outlined the damage and cause of a devastating car yard fire.
Eroad seeks $50m in deeply discounted offer
Potential Canadian raider says it won't participate.
The $1 trillion weight-loss drug that market analysts are watching
Weight-loss drugs could beef up Big Pharma's bottom line.